Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/1999
06/24/1999WO1999019359A9 Cellular receptor for hiv-1 vpr essential for g2/m phase transition of the cell cycle
06/24/1999WO1999016888A3 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
06/24/1999WO1999007728A3 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
06/24/1999WO1998052562A9 Pharmaceutical composition containing uscharidin or its analogues
06/24/1999WO1998018951A8 Receptor-mediated gene transfer system for targeting tumor gene therapy
06/24/1999CA2730373A1 Treatment of cancer having overexpression of erbb2 with anti-erbb2 antibodies and a hormonal chemotherapeutic agent
06/24/1999CA2325368A1 Proteins for cancer cell specific induction of apoptosis and method for isolation thereof
06/24/1999CA2315527A1 Human phosphatases
06/24/1999CA2315370A1 Integrin receptor antagonists
06/24/1999CA2315256A1 Needle-free injection of formulated nucleic acid molecules
06/24/1999CA2315232A1 Integrin receptor antagonists
06/24/1999CA2314884A1 Human tumor necrosis factor-r2-like proteins
06/24/1999CA2314379A1 Human dendriac and brainiac-3
06/24/1999CA2314355A1 Use of pyrazolo ¢3,4-b! pyridine as cyclin dependent kinase inhibitors
06/24/1999CA2314259A1 Multicatalytic protease inhibitors for use as anti-tumor agents
06/24/1999CA2313797A1 Heterocyclic cytotoxic agents
06/24/1999CA2313776A1 Triazine angiogenesis inhibitors
06/24/1999CA2313448A1 Ubiquitin-like conjugating protein
06/24/1999CA2309765A1 Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity
06/24/1999CA2309555A1 Selective killing and diagnosis of p53+ neoplastic cells
06/23/1999EP0924297A1 Sialoadhesin family member-2 (saf-2)
06/23/1999EP0924212A1 Chrolactomycin compound
06/23/1999EP0923941A2 Remedies for myeloma to be used together with nitrogen mustard antitumor agents
06/23/1999EP0923932A1 Composition containing antitumor agent
06/23/1999EP0923740A2 Methods and compositions for the detection of cervical cancer
06/23/1999EP0923644A1 G-coupled receptor showing selective affinity for atp
06/23/1999EP0923642A1 Active survival domains of igf-ir and methods of use
06/23/1999EP0923605A1 Conjugated mucin peptide vaccines
06/23/1999EP0923604A1 Cysteine-containing or methioine-containing peptides with immunomodulatory effects
06/23/1999EP0923585A1 Phosphinate based inhibitors of matrix metalloproteases
06/23/1999EP0923583A1 Method for producing epothilones, and intermediate products obtained during the production process
06/23/1999EP0923582A1 Substituted 6,5-hetero-bicyclic derivatives
06/23/1999EP0923570A1 Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immunosuppressives
06/23/1999EP0923564A1 Pharmaceutical compounds
06/23/1999EP0923563A1 1,4-heterocyclic metallprotease inhibitors
06/23/1999EP0923552A1 Pyranoindole and carbazole inhibitors of cox-2
06/23/1999EP0923545A1 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors
06/23/1999EP0923530A1 Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
06/23/1999EP0923529A1 Subsitute 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors
06/23/1999EP0923377A1 Therapeutic uses for an aminosterol compound
06/23/1999EP0923287A1 Nonclassical pyrrolo 2,3-d]pyrimidine antifolates
06/23/1999EP0923284A1 Cellular immunogens useful as cancer vaccines
06/23/1999EP0639186B1 Taxol derivatives
06/23/1999EP0628639B1 Reconstituted human antibody against human interleukin 6 receptor
06/23/1999EP0605522B1 Methods for the production of humanized antibodies
06/23/1999CN1220701A Lipid kinase
06/23/1999CN1220670A Inhibitor and stimulator of stem cell proliferationa and use thereof
06/23/1999CN1220660A Alkyloxyamino substituted fluorenones and their use as protein kinase cinhibitors
06/23/1999CN1220656A Novel trienoic retinoid compounds and method
06/23/1999CN1220605A Nucleotide analogues for topical treatment of proliferative disease of skin
06/23/1999CN1220266A Intermediates of protein kinase C inhibitors and preparation process thereof
06/23/1999CN1220162A Harmel preparation and preparing method thereof
06/23/1999CN1220149A Anticancer analgesic plaster and its preparing method
06/22/1999US5914411 Alternate method for acylating 10-deacetylbaccatin III selectively at the C-10 position
06/22/1999US5914406 Azepanes and their ring homologues having protein kinase inhibiting activity
06/22/1999US5914323 Treating hypercalcemia of malignancy, metastatic bone disease and/or metabolic bone disease by administering an isotonic aqueous alendronate solution with a buffer to maintain the ph in the range 4 to 8 to prevent precipitation
06/22/1999US5914314 Hyaluronic acid and its nontoxic salts facilitate penetration of immunosuppressent through underperfused or pathological tissue, including scar tissue
06/22/1999US5914251 Nucleic acid molecules encoding placental-derived growth factors
06/22/1999US5914106 Interleukin-6 receptor agonists
06/22/1999CA2256252A1 Chrolactomycin compound
06/22/1999CA2114970C Derivatives of amino-ascorbic, processes for their preparation and use
06/22/1999CA1340608C Alkoxy-4(1h)-pyridone derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
06/22/1999CA1340603C Tri-aza macrocycles and metal complexes thereof
06/20/1999CA2255143A1 Binding partners for inhibitors of cyclin-dependent kinases and their use for searching for inhibitors and for the diagnosis or therapy of a disease
06/20/1999CA2255141A1 Nucleic acid constructs for gene therapy whose activity is affected by inhibitors of cyclin-dependent kinases
06/19/1999WO1999032139A1 Improved interferon polymer conjugates
06/19/1999CA2225325A1 Hemiasterlin analogs
06/17/1999WO1999030157A2 Neuropilins in methods for diagnosis and prognosis of cancer
06/17/1999WO1999029878A2 Methods of producing anti-angiogenic proteins: endostatin, angiostatin or restin, using a pichia yeast expression system
06/17/1999WO1999029873A1 Cyclic gmp phosphodiesterase
06/17/1999WO1999029863A1 Human interferon-epsilon: a type i interferon
06/17/1999WO1999029861A1 Peptide antagonists of vascular endothelial growth factor
06/17/1999WO1999029858A1 Soluble inhibitors of vascular endothelial growth factor and use thereof
06/17/1999WO1999029856A1 Restin and methods of use thereof
06/17/1999WO1999029855A1 Mutants of endostatin, 'em 1' having anti-angiogenic activity and methods of use thereof
06/17/1999WO1999029849A1 G-protein coupled receptors associated with immune response
06/17/1999WO1999029841A1 Purification and microsequencing of hyaluronidase isozymes
06/17/1999WO1999029693A1 Imidazonaphthyridines and their use in inducing cytokine biosynthesis
06/17/1999WO1999029667A1 Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors
06/17/1999WO1999029345A1 Inhibition of tumor growth by macrophage intervention
06/17/1999WO1999029343A1 Method of treating bladder cancer with wild type vaccinia virus
06/17/1999WO1999029321A1 Inhibition of membrane-associated viral replication
06/17/1999WO1999029316A1 Pharmaceutical compositions containing an omega-3 fatty acid oil
06/17/1999WO1999029312A1 Methods for treatment of neuro- and nephro-disorders and therapeutic toxicities using aminothiol compounds
06/17/1999WO1999029309A2 2,2'-bi-1h-pyrrole derivatives useful in the treatment of leukemia brought on by htlv-i
06/17/1999WO1999029302A1 Drug delivery system with two-step targeting
06/17/1999WO1999029173A1 Composition useful for providing one-step surgical preparation and drape
06/17/1999WO1999017796A3 Modulation of lerk-2-mediated cell adhesion
06/17/1999WO1999017787A3 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
06/17/1999WO1999017742A3 Taste masked formulations
06/17/1999WO1999016887A3 Compositions and methods for identifying pkb kinase inhibitors
06/17/1999WO1999016460A3 Apolipoprotein e/growth factor complexes and methods of use
06/17/1999WO1998056919A3 Methods and reagents for vaccination which generate a cd8 t cell immune response
06/17/1999WO1998018823A8 Ice inhibiting peptides
06/17/1999DE19803206C1 New tetrakis-carboranylmethyl-propane derivatives useful in boron neutron capture tumor therapy or as labeling agents in energy filtering transmission electron microscopy
06/17/1999CA2313705A1 Restin and methods of use thereof
06/17/1999CA2313451A1 Cyclic gmp phosphodiesterase
06/17/1999CA2313450A1 G-protein coupled receptors associated with immune response
06/17/1999CA2313390A1 Peptide antagonists of vascular endothelial growth factor
06/17/1999CA2313348A1 Soluble inhibitors of vascular endothelial growth factor and use thereof
1 ... 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 ... 2211